Vadadustat

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 109 publications

A Near-Infrared Photoactivatable, Brain-Penetrant Prodrug of the Prolyl Hydroxylase Inhibitor Vadadustat for Neuroprotection in Ischemic Stroke.

A Near-Infrared Photoactivatable, Brain-Penetrant Prodrug of the Prolyl Hydroxylase Inhibitor Vadadustat for Neuroprotection in Ischemic Stroke.

Journal: Journal of medicinal chemistry

Published: May 02, 2026

Comparing Vadadustat and Darbepoetin in Maintenance Dialysis with CKD-Related Anemia: A Win Statistics Analysis.

Comparing Vadadustat and Darbepoetin in Maintenance Dialysis with CKD-Related Anemia: A Win Statistics Analysis.

Journal: Journal of the American Society of Nephrology : JASN

Published: March 17, 2026

Supramolecular host-guest interactions of TRYVIO and VAFSEO with a benzotriazole nanocapsule: A density functional theory study.

Supramolecular host-guest interactions of TRYVIO and VAFSEO with a benzotriazole nanocapsule: A density functional theory study.

Journal: Journal of molecular graphics & modelling

Published: March 16, 2026

Efficacy and safety of prolyl hydroxylase inhibitors for anemia in chronic kidney disease: a network meta-analysis.

Efficacy and safety of prolyl hydroxylase inhibitors for anemia in chronic kidney disease: a network meta-analysis.

Journal: Renal failure

Published: February 03, 2026

Barriers and Facilitators to Vadadustat Use for Managing Anemia in Adult Patients Undergoing Dialysis: A Qualitative Evidence Synthesis.

Barriers and Facilitators to Vadadustat Use for Managing Anemia in Adult Patients Undergoing Dialysis: A Qualitative Evidence Synthesis.

Journal: Cureus

Published: January 07, 2026

Impact of SLCO1B1 Gene Polymorphisms on Vadadustat Pharmacokinetics.

Impact of SLCO1B1 Gene Polymorphisms on Vadadustat Pharmacokinetics.

Journal: European journal of drug metabolism and pharmacokinetics

Published: January 02, 2026

Discovery of 3-(Arylamido)pyrazolopyridine HIF-2α Agonists and a Codrug Strategy with Prolyl Hydroxylase Inhibition for Synergistic Treatment of Renal Anemia.

Discovery of 3-(Arylamido)pyrazolopyridine HIF-2α Agonists and a Codrug Strategy with Prolyl Hydroxylase Inhibition for Synergistic Treatment of Renal Anemia.

Journal: Journal of medicinal chemistry

Published: November 21, 2025

Erythropoiesis-Stimulating Agents (ESAs) in Chronic Kidney Disease and Cancer-Related Anemia: A Narrative Review of Literature.

Erythropoiesis-Stimulating Agents (ESAs) in Chronic Kidney Disease and Cancer-Related Anemia: A Narrative Review of Literature.

Journal: Cureus

Published: September 29, 2025

Understanding Pharmacokinetic-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2024 to Better Manage the Risk of Drug Interactions With Concomitant Medications: A Review of Clinical Data From New Drug Applications.

Understanding Pharmacokinetic-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2024 to Better Manage the Risk of Drug Interactions With Concomitant Medications: A Review of Clinical Data From New Drug Applications.

Journal: Current therapeutic research, clinical and experimental

Published: August 07, 2025

Light-driven biosensor for the rapid and selective detection of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors in aqueous media and saliva.

Light-driven biosensor for the rapid and selective detection of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors in aqueous media and saliva.

Journal: Mikrochimica acta

Published: July 21, 2025

Safety and Efficacy of Vadadustat Versus Darbepoetin Alfa for Chronic Kidney Disease-Related Anemia in Patients Receiving Dialysis by Baseline Erythropoiesis-Stimulating Agent Dose.

Safety and Efficacy of Vadadustat Versus Darbepoetin Alfa for Chronic Kidney Disease-Related Anemia in Patients Receiving Dialysis by Baseline Erythropoiesis-Stimulating Agent Dose.

Journal: Hemodialysis international. International Symposium on Home Hemodialysis

Published: July 11, 2025

Network meta-analysis of HIF-prolyl hydroxylase inhibitors for anemia in dialysis-dependent and non-dialysis CKD: effects on hemoglobin, iron markers, and adverse clinical outcomes.

Network meta-analysis of HIF-prolyl hydroxylase inhibitors for anemia in dialysis-dependent and non-dialysis CKD: effects on hemoglobin, iron markers, and adverse clinical outcomes.

Journal: BMC nephrology

Published: May 26, 2025

Showing 1-12 of 109

Last Updated: 06/30/2026